Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Late morning single stock market price action burst

Tue, 12th Oct 2021 12:05

* European shares pare losses

* Wall Street futures tick up

* China's Evergrande continues to weigh

Oct 12 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

LATE MORNING SINGLE STOCK MARKET PRICE ACTION BURST (1043
GMT)

The STOXX 600 is gradually erasing most of its early losses
and making its way close to the flotation mark.

But while a -0.02% move doesn't qualify for an exciting
session for the benchmark, this doesn't mean it has been
uneventful underneath the surface.

About just an hour ago, there were pretty big and sudden
moves in London and Helsinki.

Shares in GSK jumped after Bloomberg reported private equity
firms' interest for the group's $54 billion consumer arm.

At roughly the same time, Stora Enso and
UPM-Kymmene Corporation both dropped after EU antitrust
regulators said they raided wood pulp makers in several
countries as part of a cartel investigation.

UPM just confirmed EU competition authorities were
conducting an unannounced inspection at its premises while there
were no immediate announcement from Stora Enso.

Here's what the sudden market price action looked like
(Helsinki is two hours ahead London):

(Julien Ponthus)

*****

EARNINGS SEASON FLAVOUR: VALUE! (0927 GMT)

Again? Yes again!

Calls for investors to look for value (otherwise known as
cheap) stocks have been risen seemingly as fast as German bund
and U.S Treasury yields lately.

Sell-side and buy-side analysts have been flagging that
these areas of the stock markets are typically winners when
inflation kicks in and with the earnings season opening, these
calls continue to pour in.

There's already been a few episodes of investors quickly
rotating their portfolio from growth and tech to value,
particularly last year when the COVID-19 vaccine breakthroughs
were announced in November.

According to Amundi, there's now another investing window
open across U.S. equities.

"In our view, investors will have a second chance to exploit
opportunities in the value space", wrote U.S. portfolio managers
Marco Pirondini and Alec Murray.

Stocks in the energy and financial spaces "should benefit
from higher inflation, the upward trend for commodity prices,
and a rising interest rate environment", they argue.

While tech was the ultimate winner during the first phase of
the pandemic, "higher interest rates mean a higher discount
rate, which lowers the net present value of future cash flows
for those growth names", they add.

One other argument is that "value trades at its steepest
discount to growth since 1999".

See the Amundi chart below:

(Julien Ponthus)

*****

EUROPEAN STOCKS SLIP INTO RISK-OFF (0810 GMT)

European shares slipped into risk-off mode as the energy
price crisis continued to hit sentiment ahead of the corporate
earnings season.

The pan European index STOXX 600 is down 0.6%, with
economically sensitive mining, autos and banking
sectors leading the losses, shedding more than 1%.

All the main regional indexes are also trading in negative
territory.

Declines in heavyweight mining stocks are pushing the FTSE
down 0.7% as higher energy costs, supply chain disruptions and
an imminent rate hike weigh.

Fuelling inflation fears, data showed that British employers
took their payrolls to a record high in September, while average
weekly earnings were 7.2% higher than in the same three months
of 2020, but slowing from the previous reading of 8.3%.

(Joice Alves)

*****

THE WAITING GAME (0705 GMT)

So many question marks these days: will the inflation spike
we are witnessing ebb? Will central banks resist temptation to
significantly tighten policy? How much of a dampener is $80 oil
for the world economy? Are China's property sector problems a
sign of a wider malaise?

These narratives have kept world stocks seesawing ever since
they hit record highs in early-September. Wall Street futures
are down half a percent while European shares look set for an
even weaker open. Big losses in Asia earlier, with Hong Kong
down more than 1%.

On bonds, softer growth data is failing to derail a selloff;
10-year Treasury yields are up some 30 basis points in three
weeks and on Tuesday, two-year yields touched 18-month highs.

The impact of soaring energy prices is showing up in
dataprints -- even in Japan, wholesale inflation hit a 13-year
high. British shoppers, meanwhile, upped spending by just 0.6%
in September versus 3% in August (though fuel shortages peculiar
to the UK probably had an outsize impact).

Another worrying piece of data is last month's 20% slump in
Chinese car sales, which will likely ripple out to global auto
shares. The Chinese slowdown could also make itself
felt in Germany's ZEW index later in the day.

On the bright side, UK payrolls hit a record high in
September, with a 7.2% rise in average weekly earnings in the
three months to August.

All that comes just before third quarter earnings kick off.
Remember several companies have already issued downbeat
assessments of how higher prices will have impacted the bottom
line. Q3 earnings were never expected to match the Q2 blowout
but will they fall short even of the 30% growth expected of U.S.
companies? The wait is on.

Key developments that should provide more direction to
markets on Tuesday:
-China's Evergrande missed a third round of bond payments
-Japan wholesale inflation at 13-year high in September
- UK retail spending rose 0.6% in Sept vs 3% increase
.
- IMF issues its updated World Economic Outlook
- ECB’s Chair of the Supervisory Board, Andrea Enria, board
members Philip Lane, Frank Elderson,
- Bank of Korea holds rates, flags November hike
- German ZEW
- U.S. JOLTS job openings
- U.S. Treasury auctions $96 billion in 3-year and 10-year notes

(Sujata Rao)

*****

EUROPEAN STOCK FUTURES DIP AROUND 1% (0630 GMT)

Futures are pointing to a start of the day in negative
territory for European bourses amid a global energy crunch,
clouding sentiment before the U.S. corporate earnings season.

Futures on main regional benchmarks are down around 1%,
after oil prices jumped on Monday to the highest levels in
years, fuelling inflation fears.

Also weighing on investor sentiment, Reuters reported that
some of China Evergrande Group's offshore bondholders have not
received interest payment by a Monday deadline.

(Joice Alves)

*****

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.